Puma Biotechnology Inc Stock News

Nurix Therapeutics, Inc. (NRIX) delivered earnings and revenue surprises of -26.87% and 50.67%, respectively, for the quarter ended November 2021. Do the numbers hold clues to what lies ahead for the

Which penny stocks are you watching today? The post Best Penny Stocks to Buy Today? 3 That Climbed in Premarket appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus Adagio Says Lead Monoclonal Antibody Effective Against Omicron Variant Adagio Therapeutics, Inc. (NASD

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma Biotechnology Inc (NASDAQ: PBYI ) Nerlynx (neratinib). The first update added Nerlynx to the body of the guidelines for treating adjuvant HER2-positive Breast Cancer, with Full story available on Benzinga.com

Which penny stocks are you watching today? The post Best Penny Stocks to Buy Today?

The National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology (NCCN Guidelines) has been updated for breast cancer treatment and includes two essential changes for Puma

Gainers: Puma Biotechnology PBYI +16%, Marin Software (MRIN) +9%, Midland States Bancorp (MSBI) +6%, IDEAYA Biosciences (IDYA) +3%, Ironwood Pharmaceuticals (IRWD) +3%.Losers:…

Micro-cap stock, Puma Biotechnology (PBYI) has added 12.6% in the post-market after announcing that two new updates involving its FDA-approved therapy neratinib (NERLYNX) were added to

LOS ANGELES--(BUSINESS WIRE)--A webcast of Alan Auerbach's update on Puma Biotechnology at the H.C. Wainwright BioConnect Virtual Conference, will be available beginning Jan. 10.

Equities analysts predict that Puma Biotechnology, Inc. (NASDAQ:PBYI) will post $47.70 million in sales for the current quarter, Zacks reports. Two analysts have made estimates for Puma Biotechnology’s earnings, with the lowest sales estimate coming in at $46.56 million and the highest estimate coming in at $48.84 million. Puma Biotechnology reported sales of $52.60 million […]

Wall Street brokerages forecast that Puma Biotechnology, Inc. (NASDAQ:PBYI) will report ($0.11) earnings per share (EPS) for the current quarter, according to Zacks. Two analysts have made estimates for Puma Biotechnologys earnings. The lowest EPS estimate is ($0.21) and the highest is $0.00. Puma Biotechnology reported earnings of ($0.38) per share in the same quarter []

The trading price of Puma Biotechnology Inc. (NASDAQ:PBYI) closed higher on Monday, December 13, closing at $2.94, 3.16% higher than its previous close. >> 7 Top Picks for the Post-Pandemic Economy

LOS ANGELES--(BUSINESS WIRE)--Puma Biotechnology presented an update on its Phase II SUMMIT Trial in an oral presentation at the 2021 San Antonio Breast Cancer Symposium.

The omicron variant concerns were front and center in the markets in the week ended Dec. 3, and biotech stocks did not escape the brunt of selling in the wake of the negative development. The sector r

Investors need to pay close attention to Puma (PBYI) stock based on the movements in the options market lately.